Limited HIV-1 Subtype C

3′-polypurine tract Botswana HIV-1 dolutegravir drug resistance mutations nef

Journal

Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317

Informations de publication

Date de publication:
13 Aug 2021
Historique:
received: 28 05 2021
revised: 05 08 2021
accepted: 11 08 2021
entrez: 28 8 2021
pubmed: 29 8 2021
medline: 29 8 2021
Statut: epublish

Résumé

Dolutegravir (DTG) is a potent anti-HIV drug that is used to treat HIV globally. There have been reports of mutations in the HIV-1 3'-polypurine tract (3'PPT) of the

Identifiants

pubmed: 34451492
pii: pathogens10081027
doi: 10.3390/pathogens10081027
pmc: PMC8400509
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : FIC NIH HHS
ID : D43TW010543
Pays : United States
Organisme : NIH HHS
ID : NIH K24 AI131928
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI131928
Pays : United States
Organisme : Wellcome Trust
ID : DEL-15-006
Pays : United Kingdom
Organisme : FIC NIH HHS
ID : D43 TW009610
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001911
Pays : United States
Organisme : CGH CDC HHS
ID : U01 GH000447
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States

Références

Nat Med. 1996 Mar;2(3):338-42
pubmed: 8612235
J Virol. 2020 Feb 14;94(5):
pubmed: 31776273
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
Retrovirology. 2013 Oct 30;10:125
pubmed: 24172637
Int J Mol Sci. 2020 Feb 25;21(5):
pubmed: 32106437
PLoS One. 2019 Nov 21;14(11):e0224292
pubmed: 31751353
Retrovirology. 2017 Jun 5;14(1):36
pubmed: 28583191
J Antimicrob Chemother. 2019 Dec 1;74(12):3440-3444
pubmed: 31730161
J Virol. 1994 May;68(5):3092-101
pubmed: 8151774
Bioinformatics. 2019 May 15;35(10):1763-1765
pubmed: 30295730
Retrovirology. 2018 Aug 17;15(1):56
pubmed: 30119633
N Engl J Med. 2019 Jul 18;381(3):230-242
pubmed: 31314967
J Virol. 2004 Dec;78(23):13315-24
pubmed: 15542682
Virology. 2007 Apr 10;360(2):341-9
pubmed: 17123564
mBio. 2018 Apr 10;9(2):
pubmed: 29636435
J Infect Dis. 2018 Jul 24;218(5):688-697
pubmed: 29617822
Nature. 1991 Apr 11;350(6318):508-11
pubmed: 2014052
Antimicrob Agents Chemother. 2021 May 18;65(6):
pubmed: 33722887
mBio. 2017 Sep 26;8(5):
pubmed: 28951475
Viruses. 2021 Mar 31;13(4):
pubmed: 33807382
Lancet. 2013 Mar 2;381(9868):735-43
pubmed: 23306000

Auteurs

Kaelo K Seatla (KK)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Faculty of Health Sciences, School of Allied Health Professions, University of Botswana, Gaborone, Botswana.

Dorcas Maruapula (D)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Faculty of Health Sciences, School of Allied Health Professions, University of Botswana, Gaborone, Botswana.

Wonderful T Choga (WT)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Division of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.

Olorato Morerinyane (O)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Shahin Lockman (S)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Vladimir Novitsky (V)

The Warren Alpert Medical School of Brown University, Providence, RI 12321, USA.
Division of Infectious Diseases, The Miriam Hospital, Providence, RI 23324, USA.

Ishmael Kasvosve (I)

Faculty of Health Sciences, School of Allied Health Professions, University of Botswana, Gaborone, Botswana.

Sikhulile Moyo (S)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Simani Gaseitsiwe (S)

Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Classifications MeSH